Merck Signs MoU for BioProcessing Production Center in South Korea

Merck, a science, and technology company signed a non-binding memorandum of understanding (MoU) with the Ministry of Trade, Industry and Energy (MOTIE), and Daejeon City for a new Asia-Pacific BioProcessing Center, aimed at supporting the region’s healthcare ecosystem.

The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific. 

“South Korea is an emerging global leader in the biotech industry, and this Memorandum of Understanding demonstrates Merck’s commitment to the region by working closely with the government to better support our customers,” said, Matthias Heinzel, member of the executive board of Merck and CEO, Life Science. “The proposed facility would play a vital role in fulfilling demand in the Asia-Pacific region while representing an important hub for further biopharma industry development in South Korea.”

Chang Yang Lee, minister of trade, industry & energy, said, “We expect this collaboration to serve as an opportunity for our pharmaceutical-bio sector to take a leap forward as the science and technology industry of South Korea.”

Merck plans to work with the Daejeon government to support biotech companies based in the Daedeok Research Complex located in Daejeon, as well as expand the bio-research cooperation with leading Korean universities.